Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1997-10-24
2003-10-28
Russel, Jeffrey E. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800
Reexamination Certificate
active
06638909
ABSTRACT:
The present invention relates to the use of alpha-1-antitrypsin (AAT) for the preparation of compositions for the treatment of chronic wounds.
alpha-1-antitrypsin (AAT), also known as alpha-1-proteinase inhibitor or serpin, is a mammalian polypeptide having a molecular weight of approximately 54 kDa. It is a potent fluid phase inhibitor of serine proteases, and forms a tightly bound, stoichiomedric complex with elastase. It can be inactivated by cleavage within its reactive centre. For example, neutrophil collagenase (MMP8) is know to degrade and inactivate AAT.
AAT deficiency is a congenital disorder that is principally associated with liver disease in children and emphysema in young adulthood. It is thought that AAT deficiency results in loss of protection in the lung against neutrophil elastase, resulting in breakdown of the architecture of the lung. AAT has been administered in intravenous and aerosol formats for the treatment of pulmonary emphysema.
It is an object of the present invention to provide improved compositions for the treatment of chronic wounds, such as decubitis ulcers, pressure sores and venous ulcers.
The present invention provides the use of alpha-1-antitrypsin for the preparation of a composition for the treatment of a chronic wound.
Preferably, the composition is a wound dressing composition. That to say, the composition is preferably a liquid, semi-solid or solid composition for application directly to the surface of a wound, or the composition is applied to the surface of, or incorporated into, a solid wound contacting layer such as a wound dressing gauze or film. More preferably, the wound dressing composition is a fluid or a gel comprising from 100 ng to 10 mg/ml, preferably 10 &mgr;g to 1 mg/ml of AAT in combination with conventional pharmaceutical excipients for topical application to a wound. Suitable carriers include: Hydrogels containing cellulose derivatives, including hydroxyethyl cellulose, hydroxymethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose and mixtures thereof; and hydrogels containing polyacrylic acid (Carbopols). Suitable carriers also include creams/ointments used for topical pharmaceutical preparations, e.g. creams based on cetomacrogol emulsifying ointment. The above carriers may include alginate (as a thickener or stimulant), preservatives such as benzyl alcohol, buffers to control pH such as disodium hydrogen phosphate/sodium dihydrogen phosphate, agents to adjust osmolarity such as sodium chloride, and stabilisers such as EDTA.
Alternatively, the wound dressing composition may be a slow release solid composition, in which the AAT is dispersed in a slow release solid matrix such as a matrix of alginate, collagen, or a synthetic bioabsorbable polymer. Preferably, the wound dressing composition is sterile.
Preferably, the chronic wound is selected from the group consisting of venous ulcers, pressure sores, decubitis ulcers, diabetic ulcers and chronic ulcers of unknown etiology. Preferably, the chronic wound is not a periodontal disease condition.
It is to be understood that the term “alpha-1-antitrypsin” as used herein encompasses all naturally occurring polymorphs of AAT. It also encompasses functional fragments of AAT, chimeric proteins comprising AAT or functional fragments thereof, homologs obtained by analogous substitution of one or more amino acids of AAT, and species homologs. Preferably, the AAT is a product of recombinant DNA technology, and more preferably the AAT is a product of transgenic technology. For example, the gene coding for AAT can be inserted into a mammalian gene encoding a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland, as described in WO88/00239.
Without wishing to be bound by any theory, it is thought that the AAT improves the healing of chronic wounds by inhibiting human neutrophil elastase present in the wound. The healing of such wounds is determined by a complex balance between tissue formation and tissue destruction, and it appears that inhibition of neutrophil elastase by AAT shifts the balance in favour of wound healing.
In another aspect, the present invention provides a method for the treatment of chronic wounds as specified above, the method comprising administering a therapeutically effective amount of AAT to the patient. Preferably, the AAT is administered topically, more preferably in a topical composition as described above.
REFERENCES:
patent: 4377572 (1983-03-01), Schwarz et al.
patent: 4829052 (1989-05-01), Glover et al.
patent: 5134119 (1992-07-01), Lezdey et al.
patent: 5202118 (1993-04-01), Gillis et al.
patent: 097 274 (1984-01-01), None
patent: 103 409 (1984-03-01), None
patent: 114 777 (1984-08-01), None
patent: 139 383 (1985-05-01), None
patent: 169 114 (1986-01-01), None
patent: 173 619 (1986-03-01), None
patent: 067 293 (1986-06-01), None
patent: 222 726 (1987-05-01), None
patent: 224 811 (1987-06-01), None
patent: 253 690 (1988-01-01), None
patent: 298 807 (1989-01-01), None
patent: 304 971 (1989-03-01), None
patent: 149 872 (1989-05-01), None
patent: 319 944 (1989-06-01), None
patent: 127 535 (1990-01-01), None
patent: 414 605 (1991-02-01), None
patent: 420 600 (1991-04-01), None
patent: 436 086 (1991-07-01), None
patent: 137 633 (1991-12-01), None
patent: 473 502 (1992-03-01), None
patent: 171 142 (1992-07-01), None
patent: 221 426 (1992-08-01), None
patent: 282 363 (1992-09-01), None
patent: 218 090 (1992-12-01), None
patent: 288 841 (1992-12-01), None
patent: 562 863 (1993-09-01), None
patent: 566 158 (1993-10-01), None
patent: 155 188 (1993-12-01), None
patent: 164 556 (1994-03-01), None
patent: 284 044 (1994-03-01), None
patent: 432 117 (1994-06-01), None
patent: 480 906 (1995-04-01), None
patent: 648 838 (1995-04-01), None
patent: 698 615 (1996-02-01), None
patent: 717 049 (1996-06-01), None
patent: 2 150 433 (1985-07-01), None
patent: 2 239 315 (1994-01-01), None
patent: 88/00239 (1988-01-01), None
patent: WO 89 11285 (1989-11-01), None
patent: WO 91 07166 (1991-05-01), None
patent: WO 91 07490 (1991-05-01), None
patent: WO 91 07983 (1991-06-01), None
patent: WO 92 06706 (1992-04-01), None
patent: WO 92 19730 (1992-11-01), None
patent: WO 93 03769 (1993-03-01), None
patent: WO 93 13795 (1993-07-01), None
patent: WO 94 07525 (1994-04-01), None
patent: WO 94 13318 (1994-06-01), None
patent: WO 94 16073 (1994-07-01), None
patent: WO 94 26781 (1994-11-01), None
patent: WO 94 26896 (1994-11-01), None
patent: WO 95 11987 (1995-05-01), None
patent: WO 95 24428 (1995-09-01), None
patent: WO 95 35306 (1995-12-01), None
patent: WO 96 10638 (1996-04-01), None
patent: WO 96 28008 (1996-09-01), None
patent: WO 96 29988 (1996-10-01), None
patent: WO 96 40224 (1996-12-01), None
patent: WO 97 09350 (1997-03-01), None
The Journal of Investigative Dermatology—Rao et al. vol. 105 Oct. 1, 1995, pp. 572-578.
Bloor Stephen
Doyle Peter J.
Grady Michael W.
Ethicon Inc.
Russel Jeffrey E.
LandOfFree
Wound healing compositions containing alpha-1-antitrypsin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Wound healing compositions containing alpha-1-antitrypsin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Wound healing compositions containing alpha-1-antitrypsin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3166142